Table 2 Number of PET–CTs in which ‘added value’ was detected compared to conventional imaging (MRI/CT) according to sarcoma subtype
Sarcoma pathological diagnosis | Percentage of PET–CT with added value | Number of PET–CT with added value over MRI/CT | ||
|---|---|---|---|---|
Staging | Restaging | Treatment response | ||
Undifferentiated pleomorphica | 13.3% (22/166) | 6 | 11 | 5 |
Angiosarcomab | 9% (1/11) | 1 | 0 | 0 |
Leiomyosarcoma | 18% (30/166) | 7 | 14 | 9 |
Rhabdomyosarcoma | 24.6% (13/53) | 3 | 2 | 8 |
Myxofibrosarcoma | 26.7% (8/30) | 0 | 5 | 3 |
Epithelioid sarcoma | 13% (3/23) | 1 | 2 | 0 |
Osteosarcoma | 23.5% (23/98) | 6 | 9 | 8 |
Clear cell sarcoma | 12.5% (1/8) | 1 | 0 | 0 |
Ewing sarcoma/DSRCT | 27.5% (33/120) | 7 | 12 | 14 |
Synovial sarcoma | 13.6% (6/44) | 3 | 2 | 1 |
De-differentiated liposarcoma | 8.3% (3/36) | 1 | 1 | 1 |
Solitary fibrous tumour | 28% (7/25) | 0 | 5 | 2 |
Chondrosarcoma grade 2/3 | 24.4% (11/45) | 3 | 5 | 3 |
Myxoid/round cell liposarcoma | 11.1% (4/36) | 2 | 1 | 1 |
Alveolar soft part sarcoma | 25% (1/4) | 1 | 0 | 0 |
MPNST | 41.6% (27/65) | 14 | 9 | 4 |
Low grade soft tissue sarcoma | 0% (0/17) | 0 | 0 | 0 |
Chondrosarcoma grade 1 | 0% (0/10) | 0 | 0 | 0 |
Total | 21% (193/930) | 56 | 78 | 59 |